Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Author(s):
Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; D'Amico, R.; Fyles, A.; Baron, M.H.; Jurgenliemk-Schulz, I.M.; Kitchener, H.C.; Nijman, H.W.; Wilson, G.; Brooks, S.; Gribaudo, S.; Provencher, D.; Hanzen, C.; Kruitwagen, R.F.; Smit, V.T.H.B.M. (0000-0003-3730-5652); Singh, N.; ; Lissoni, A.; Nout, R.A.; Feeney, A.; Verhoeven-Adema, K.W.; Putter, H.; Creutzberg, C.L.; PORTEC Study Grp
Published
2019
Publication type
Article / Letter to editor
Date issued
2019-09-30
Language
English
Is part of
The Lancet Oncology (2019), Vol. 20, no. 9, p. 1273-1285
hdl
1887/121346
doi
10.1016/S1470-2045(19)30395-X